Pulmonary Fibrosis

Latest News

Beyond well-characterized cellular and molecular pathways, the authors explore the emerging significance of non-coding RNAs. | Image credit: PRASANNAPIX - stock.adobe.com
Insights Into Pulmonary Fibrosis Pathogenesis, Treatments, and the Potential Role of Traditional Chinese Medicine

August 5th 2025

From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

The investigators said they believe their scoring system to be a useful tool that will improve patient care. | Image Credit: mi_viri
AIM-30 Score Predicts Mortality Following Acute Exacerbation of IPF

July 30th 2025

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com
Setting Care Goals Early Is Key in Pulmonary Fibrosis

July 29th 2025

The findings showed that certain IPF phenotypes had a significant association with hypothyroidism. | Image credit: surasak - stock.adobe.com
Immune Cell Phenotypes Linked With Hypothyroidism, IPF

July 23rd 2025

Genomics and metabolomics have sparked an opportunity to find biomarkers that might make it easier to diagnose idiopathic pulmonary fibrosis at an earlier stage. | Image credit: PRASANNAPIX - stock.adobe.com
Metabolites With Potential Role in IPF Identified by Genome-Wide Association Study

July 9th 2025

Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making

Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need for earlier diagnosis and improved care coordination; and emerging therapies that may close treatment gaps.

AJMC Peer Exchange logo displayed on a blue geometric background with layered diamond shapes.

More News

Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds
January 25th 2020

Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds

Alison Rodriguez
Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.
Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis
January 17th 2020

Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis

Matthew Gavidia
Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.
Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF
May 18th 2019

Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF

Samantha DiGrande
In a study to be presented at the American Thoracic Society (ATS) Annual Meeting, held in Dallas, Texas on May 17-22, 2019, researchers investigated visit-to-visit variability in the forced vital capacity (FVC) of patients with idiopathic pulmonary fibrosis (IPF).
Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF
May 10th 2019

Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF

Samantha DiGrande
During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet) in the treatment of idiopathic pulmonary fibrosis (IPF) in a real-world setting.
<123

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo